Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for posting this. I don’t short stock so didn’t realize the uptick rule had been eliminated - I still see ticks displayed - must be for old times sake. No wonder there’s still so much cash still sitting on the sideline with volatility and 24 hour news cycle - enough to keep retail investors away
Thank you for your service. Your experiences put this investment in the proper perspective. We must have hope. I felt such a relief taking some of my holdings off the table when I was a little unsure. My decision. Nothing wrong with banking losses to use for the day when our decision about investing in this company, in this hope for a cure, albeit somewhat early for many of us, becomes the right decision.
I don’t know what financing options are available to them.. Dr Nadar Pourhassen is tenaciousness and he’s run this company on a shoestring budget through outsourcing. We’re not going to get institutional interest until we have revenue. With Dr Richard Pestell joining the team we once again have a well articulated vision and the capability to see that vision fulfilled. Unless you have 4 myn shares you have no control. Don’t beat yourself up over something you can’t control. We’ve made tremendous progress since 2009. I’ve jumped back in with both feet.
Thank you, but unfortunately I don’t think I’m the exception. There are many families affected by cancer and HIV. Emotionally Searching for a Rainbow.
Thank you.
Thanks for sharing this. I hope it’s spread widely and gives hope to those without hope. My mother in law died from breast cancer. It was a very sad day when she told us she’d decided to stop her treatment as she couldn’t tolerate it. She was gone in three weeks. My father had prostate cancer and was always wondering if his doctors approach to monitor his PSA levels was the best course of action for him. After watching this video, I know the test Dr Pestell designed would have removed the doubt and worry from my dad’s final years. Thankful all the pieces are finally in place.
Great news - Happy Thanksgiving Longs!
Yes, I wonder if Prostagene or Dr. P2 had received any revenue from that. https://www.ncbi.nlm.nih.gov/pubmed/22637726
The market makers appear to be trying to pry stock away from longs. There's not a lot of volume but the bid and ask are inching up. Very interesting.
I've found this site has a good collection of news on the company.
https://www.proactiveinvestors.com.au/ASX:BIT/Biotron/
Thank you. He continues the good fight started by Dr Allen D Allen. I pray the business side is completed and gets out of the way of these people with great vision.
Thanks for the update!
Actually they're down due to this, https://www.marketwatch.com/story/gilead-shares-drop-after-new-unitedhealth-program-incentivizes-cheaper-hiv-meds-2018-10-31
Interesting, alarming, and unbelievable that it’s permitted to continue.
Big hurt!
What I read pointed to the market makers and DTC as the parties involved in naked shorting. My background is operation/ compliance and I believe it can be done but don’t understand why it’s permitted. DTC is a relatively young organization, who are they paying to permit this crap. Does our share price factor into the acquisition? The joint dog and pony show with Dr Ps, the research into naked shortselling, Nader saying the deal would be done in weeks on the conference call and then booking a shareholder meeting when Dr P was overseas giving a presentation, and not much mention of our company in his bio at this conference spooked me. Makes me wonder if the share price has to reach a certain milestone, or they were testing how much $ they could raise .
I'd be on both boards. I've been here longer than Nader and have recently trimmed my position. I think it would be easier to get back in than get out, and I've held enough to celebrate if all goes as hoped.
If anyone read the Forbes piece I posted it said the pay for a biotech CEO is tied to the amount of money the CEO has raised; not one word in that article about share price. As a shareholder that doesn't make me happy, but clinical biotechs are different. Has anyone tallied the cash raises that Dr. P has brought in since CEO?
Conversely, what does jump out of he article is the amount of funds available in 2018 and it doesn't appear we've tapped that and Dr. P said on the last call that he's following the direction of the board.
Well that’s the problem, there’s no reporting, so just speculation. I don’t think Canada’s situation has any affect other than the company powering their transactions would be knocking on the door of every state where it is legal and with a very strong track record of successful transaction and tax reporting to the Canadian government. I was happy to see the former Florida legislature get on board a few months back, but the company has obligations and they’re not meeting them according to a few brokerage houses and the OTC markets. I wish you all good luck and hope you prosper.
Bloomberg showed .54 with 112,570 volume, and then it just updated to live with a volume of 364
Could that be a tactic used by the naked short sellers? Those are public numbers.
Fidelity’s Risk department blocked it. If you look at the OTC website it states that the company is dark or defunct. I expect they are busy, but they are lawyers and should understand the importance of corporate filing and reporting. If they want to be in the game, they can’t ignore the details. I’m not happy about selling, but I had over 50k shares and with the ability to buy becoming limited who would I sell to?
I've been reading what's been posted regarding naked/phantom shorting and found this article very interesting and its relatively recent:
https://blockchainatberkeley.blog/blockchain-for-securities-trading-black-swan-or-in-house-pet-618ee382f076
I looked at the conference website and nothing was posted there.
I tried to buy more at Fidelity and was blocked from buying, could only sell. May regret my decision, but I sold.
While I'm excited about the prostate cancer test, after the last conference call I think I incorrectly jumped to the conclusion that Prostagene was already in discussions with Labcorp and Quest about using it. Was he simply getting an indication of interest? It that normal to be in discussions when we're just now going to go to the FDA? Or are they testing something different than what Dr. Pestell was referring to on the conference call.
Didn't Dr. P say during last conf call the new pivotal design was based on a test for Chrons which got the format approved by FDA. That together with their number crunching the various dosing levels and determining the weeks in trail and success/failure for participant led me to believe they had a better avenue for success with the new trial design. I don't know that it was a negative or the realization of a better path forward.
My positive takeaways - Drs. Pourhassan and Pestell are collaborating and there is a respect for the talents each brings and a desire to learn and move forward. Dr. Pestell has one test close to marketability and has ideas for additional tests. That makes me think of a fledgling Illumina or Thermo Fisher. May be a reach but owning a clinical biotech with revenue removes some risk for me.
I’m encouraged. They’re basing the format of the new mono pivotal trail on a Crohn’s disease test format - 6 weeks indicative , they’ll screen candidates in that round and then move to the 24 weeks of maintenance. A very cost effective strategy IMHO. And we may have revenue - REVENUE - in 2019 from the prostate testing.
I'm very optimistic with the changes that are taking place, but haven't had a chance to develop and grow. For example, Dr. Pestell is acting CMO and we expect great things from him and his scientific vision. He earned his MBA from NYU. Look at his ProstaGEne website, he established three advisory boards: Scientific, Clinical and Business. Look at the business advisory board and read the bio for Edward Glickman, Professor of Finance at the Stern School of Business NYU, with past experience as an investment banker. Dr. Pourhassan has driven this on a shoestring budget and I believe he'll listen to the experts on the board of CYDY re finance as well as the Business Advisory board of the company we are purchasing. In my humble, novice opinion, this is just starting to germinate into what it will become. Unfortunately, shareholder dilution with a clinical stage biotech is to be expected, and its painful, but that's how many of us can afford to get in. Stay strong, stay long.
Yes. I’m a believer.
That's not proper
I know, Right?
At Merrill the old limit was $5; minimum trade and minimum balance in the account,plus signed forms. A hassle. The meltdown changed many things including the rise of firms with $4.95 trading commission, or 100 free trades, etc. it has also freightened masses to hang on to cash paying zero. I stumbled upon CYDY in 09 while commiserating with a colleague about how we’ll reinvent ourselves again. He said well if you think we have it bad I know a friend at a firm with the cure for aids..... my point is this investment carries a lot of risk and if it didn’t, many would be priced out. The risk would prevent me from recommending this.
Many major wire houses don’t permit trading penny stocks. If your account is at Merrill Lynch, for example, you may be prohibited and just assume that’s the way it is.
Vacation GTC orders
Couldn’t find anything for you on company websites.
He said they'd ask to convert, no guarantee.
This is a long haul, against the wind. You have to have the proper asset allocation to be able to assume the risk associated with investing in a clinical biotech.
Thankful for the expertise our newest board member brings. In my long term view, the pieces are lining up nicely.
FWIW - CFO sold stock July 9 & 10. Cramer panned it - so its probably a buy - just kidding - no clue.